View : 83 Download: 0
A retrospective analysis for patients with HER2-positive gastric cancer who were treated with trastuzumab-based chemotherapy: In the perspectives of ethnicity and histology
- A retrospective analysis for patients with HER2-positive gastric cancer who were treated with trastuzumab-based chemotherapy: In the perspectives of ethnicity and histology
- Yi J.H.; Kang J.H.; Hwang I.G.; Ahn H.K.; Baek H.J.; Lee S.I.; Lim D.H.; Won Y.-W.; Ji J.H.; Kim H.S.; Rha S.Y.; Oh S.Y.; Lee K.E.; Lim T.; Maeng C.H.; Kim M.J.; Kim S.T.; Lee J.; Park J.O.; Park Y.S.; Lim H.Y.; Kang W.K.; Park S.H.
- Ewha Authors
- SCOPUS Author ID
- Issue Date
- Journal Title
- Cancer Research and Treatment
- vol. 48, no. 2, pp. 553 - 560
- ErbB-2 receptor; Ethnic groups; Histology; Stomach neoplasms; Trastuzumab
- Korean Cancer Association
- SCIE; SCOPUS; KCI
- Purpose While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy. Materials and Methods Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively. Results A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the male:female ratio was 118 (70.2%):50 (29.8%). Fourteen (8.3%), 63 (37.5%), 75 (44.6%), and 11 (6.5%) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6%. The median progression-free survival (PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025). Conclusion While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer. © 2016 by the Korean Cancer Association.
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.